+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

Results for tag: "Cancer Monoclonal Antibodies"

Bispecific Antibodies for Cancer Market 2025-2029 - Product Thumbnail Image

Bispecific Antibodies for Cancer Market 2025-2029

  • Report
  • February 2025
  • 233 Pages
  • Global
From
From
From
From
From
From
Engineered Antibody Therapeutics for Cancer - Product Thumbnail Image

Engineered Antibody Therapeutics for Cancer

  • Report
  • July 2024
  • Global
From
Anthracycline Market Report 2025 - Product Thumbnail Image

Anthracycline Market Report 2025

  • Report
  • March 2025
  • 200 Pages
  • Global
From
Metastatic Cancer Drugs Market Report 2025 - Product Thumbnail Image

Metastatic Cancer Drugs Market Report 2025

  • Report
  • February 2025
  • 200 Pages
  • Global
From
From
From
Head and Neck Cancer (HNC) Pipeline Analysis Report - Product Thumbnail Image

Head and Neck Cancer (HNC) Pipeline Analysis Report

  • Report
  • August 2024
  • 150 Pages
  • Global
From
Cancer Immunotherapy Market 2024-2028 - Product Thumbnail Image

Cancer Immunotherapy Market 2024-2028

  • Report
  • July 2024
  • 180 Pages
  • Global
From
From
From
Loading Indicator

Cancer Monoclonal Antibodies (mAbs) are a type of oncology drug used to treat cancer. They are a type of biologic therapy, which means they are made from living cells. mAbs are designed to target specific proteins on cancer cells, which can help to slow or stop the growth of the cancer. They can be used alone or in combination with other treatments, such as chemotherapy or radiation therapy. mAbs can be used to treat a variety of cancers, including breast, lung, and colorectal cancer. The Cancer Monoclonal Antibodies market is a rapidly growing segment of the oncology drugs market. mAbs are becoming increasingly popular due to their ability to target specific proteins on cancer cells, which can help to reduce side effects and improve outcomes. Additionally, mAbs are often more cost-effective than other treatments, making them attractive to healthcare providers. Some of the major companies in the Cancer Monoclonal Antibodies market include Roche, Merck, Bristol-Myers Squibb, Amgen, and Novartis. Show Less Read more